Penserra Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3K | Sell |
12
-1,208
| -99% | -$302K | ﹤0.01% | 900 |
|
|
2025
Q1 | $329K | Buy |
1,220
+1,208
| +10,067% | +$326K | 0.01% | 657 |
|
|
2024
Q4 | $2K | Sell |
12
-2,401
| -100% | -$400K | ﹤0.01% | 1064 |
|
|
2024
Q3 | $663K | Sell |
2,413
-8,414
| -78% | -$2.31M | 0.01% | 493 |
|
|
2024
Q2 | $2.63M | Buy |
10,827
+10,818
| +120,200% | +$2.63M | 0.03% | 319 |
|
|
2024
Q1 | $1K | Hold |
9
| – | – | ﹤0.01% | 1159 |
|
|
2023
Q4 | $1K | Hold |
9
| – | – | ﹤0.01% | 1212 |
|
|
2023
Q3 | $1K | Buy |
9
+3
| +50% | +$333 | ﹤0.01% | 1210 |
|
|
2023
Q2 | $1K | Hold |
6
| – | – | ﹤0.01% | 1225 |
|
|
2023
Q1 | $1K | Hold |
6
| – | – | ﹤0.01% | 1021 |
|
|
2022
Q4 | $1K | Buy |
+6
| New | +$1K | ﹤0.01% | 1072 |
|
|
2017
Q1 | – | Sell |
-336
| Closed | -$12K | – | 557 |
|
|
2016
Q4 | $12K | Buy |
336
+70
| +26% | +$2.5K | ﹤0.01% | 749 |
|
|
2016
Q3 | $18K | Buy |
266
+106
| +66% | +$7.17K | ﹤0.01% | 555 |
|
|
2016
Q2 | $9K | Buy |
160
+57
| +55% | +$3.21K | ﹤0.01% | 715 |
|
|
2016
Q1 | $6 | Buy |
+103
| New | +$6 | ﹤0.01% | 574 |
|